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Multiple primary tumors were first described by Billroth at the end of the 19th century.1,2 He described a patient with stomach cancer 
who was later found to harbor a malignant tumor of 
the external ear.3 Secondary to the significant improve-
ments in the diagnosis and treatment of cancer, a higher 
proportion of surviving cancer patients are at risk of 
developing a second, third or even higher number of 
primary malignancies. The study of multiple primary 
malignant tumors is of paramount importance since it 
could unravel clinical associations of certain malignan-
cies, uncover various germ-line and genetic mutations 
and help tailor follow-up and screening in these pa-
tients.4,5 Even though there is an adequate body of pub-
lished data describing the epidemiological and clinical 
characters of patients with two primary malignancies, 
there is a scarcity of reports addressing patients with 
three or more malignancies. We present an extremely 
rare clinical scenario: a patient with eight primary ma-
lignant tumors and we reviewed the relevant literature 
in an attempt to highlight the epidemiological features, 
pathological characters, therapeutic regimens and dis-
ease outcomes of this poorly understood disease entity.
CASE 
Our patient was a 59-year-old female with Crohn dis-
ease with an otherwise non-contributory medical his-
tory. At the age of 50 she presented with menorrhagia. 
Eight primary malignancies: case report and 
review of literature
The incidence of multiple primary malignancies has increased over the past years secondary to the long-
term survival of cancer patients due to improvements in the early detection and adequate treatment of 
cancer. We present a patient with eight primary malignant tumors and review the relevant literature. Our 
patient was a 59-year-old female with Crohn disease with an otherwise non-contributory medical history. 
Risk factors for multiple primary tumors were not detected in our patient. At a follow-up of 108 months 
from the time of diagnosis of the first malignancy, our patient was still alive. Similar long-term survival 
has been reported in the literature. Due to the realistic potential for long-term survival, we recommend 
aggressive treatment of these patients.
Ahmed Slem, Ramiz Abu-Hijlih, Fadwa Abdelrahman, Rim Turfa, Rula Amarin, Naim Farah, Maher 
Sughayer, Abdelatief Almousa, Jamal Khader
From the King Hussein Cancer Center, Amman, Jordan
Correspondence: Jamal Khader � King Hussein Cancer Center, Amman Jordan � jkhader@khcc.jo � Accepted: June 2011
Hematol Oncol Stem Cell Ther 2011; 4(4): 185-187
DOI: 10.5144/1658-3876.2011.185
Pelvic ultrasound demonstrated endometrial thicken-
ing. She underwent total abdominal hysterectomy with 
preservation of both ovaries. Histopathology revealed 
International Federation of Gynecology and Obstetrics 
(FIGO) stage I endometrial adenocarcinoma. At the 
age of 51 she was found to have a cecal mass on lower 
gastrointestinal colonoscopy. Computed tomogra-
phy (CT) of the abdomen showed a 3-cm concentric 
thickening of the cecum and ascending colon. She un-
derwent right hemicolectomy. Histopathology revealed 
moderately differentiated papillary adenocarcinoma 
invading through the musclaris propria into the subse-
rosa, and staging of T3N0M0. No further treatment 
was offered. At the age of 54 years she presented with 
hematuria. A CT scan of the abdomen demonstrated a 
4-cm T1N0M0 right renal cell carcinoma that was sub-
sequently treated by right nephrectomy. Three months 
later she presented with bloating and abdominal pain. 
Magnetic resonance imaging of the abdomen and pelvis 
showed a matted 8×9 cm right pelvic mass suggestive 
of an ovarian tumor. She underwent surgical excision 
and was found to harbor FIGO stage IA right ovar-
ian, moderately differentiated adenocarcinoma with 
pathological and immuno-histochemical features dis-
tinguishing this primary from the previously diagnosed 
endometrial cancer. She received 4 cycles of adjuvant 
carboplatin and paclitaxel. At the age of 55 years she 
presented with invasive lobular carcinoma of the left 
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breast and was treated by surgical excision. She did not 
receive any further treatment. At the age of 56 years a 
routine follow-up chest CT scan demonstrated 2×2.5-
cm left upper lobe lung nodule. She underwent lo-
botomy that revealed a T2N0M0 bronchoalveloar ad-
enocarcinoma with free surgical margins. At the age of 
57 years she was found to harbor a right ureteric mass 
on routine follow-up pelvic CT and was subsequently 
treated by right ureterectomy. Histopathology demon-
strated invasive high-grade transitional cell carcinoma 
with extension to peri-ureteric adipose tissue and free 
resection margins; stage pT3N0M0. One month later 
she presented with an ulcer at the right nostril. Surgical 
excision revealed moderately differentiating squamous 
cell carcinoma with free surgical margins. At the age 
of 58 years she presented with a retroperitoneal mass 
on follow-up CT scan of the abdomen and pelvis. 
Histopathological examination of an open surgical bi-
opsy specimen revealed findings consistent with recur-
rent transitional cell carcinoma. She received six cycles 
of carboplatin and paclitaxel. At the time of writing 
(108 and 12 months from the time of diagnosis of the 
first and last primary tumor respectively), she was alive 
with evidence of residual retroperitoneal disease.
DISCUSSION 
The exact incidence of patients presenting with at least 
three primary tumors remains unknown. Rosso et al.6 
extracted data from 69 European cancer registries. Out 
of a total 2 919 023 malignant cancers cases; 183 683 
(6.3%) cases of multiple primary tumors (at least two 
tumors) were found. It has been estimated that ap-
proximately 2% to 12% of patients with two tumors 
go on to develop a third or fourth neoplasm.7,8 In the 
study by Bittorf and colleagues,9 57 (0.1%) of 52 398 
included patients harbored at least three primary neo-
plasms. This corresponds to 2.8% of patients with two 
primary tumors. 
For the accurate classification of multiple primary 
tumors, each tumor must exhibit a definite picture 
of malignancy, each tumor must represent a distinct 
clinical entity and the probability that one is a result 
of metastatic spread from the other must be reliably 
excluded.10 However, multiple tumors demonstrating 
similar histological sub-classification could correctly be 
labeled as multiple primaries if they arise from differ-
ent anatomical subsites.11 A new malignant tumor can-
not be classified as a secondary neoplasm if it occurs 
in the same anatomical location as the first tumor.12 
Nonetheless, tumors arising from the same anatomical 
site could be considered multiple if they possess vary-
ing histologies.11 Tumors are labeled as simultaneous if 
both/all are discovered at the same time, synchronous 
if discovered within 6 months of the first or metachro-
nous if recognized more than 6 months after the dis-
covery of the first tumor.10 
Risk factors for multiple primary tumors include 
genetic, constitutional and environmental factors. 
None were detected in our patient. Unfortunately, 
our patient did not undergo detailed genetic testing to 
uncover possible underlying genetic mutations. Even 
though our patient exhibited at least three primary tu-
mors with direct etiological links to smoking, she said 
she was a never-smoker. 
Some investigators have postulated that the oc-
currence of a subsequent cancer in surviving cancer 
patients has probably increased over the past years sec-
ondary to the substantially improved treatment, and 
the subsequent long-term survival expected in patients 
with this disease.6 Due to the rarity of occurrence of 
multiple primary tumors, accurately highlighting such 
a temporal trend would prove difficult. However, it is 
well known that the treatment of cancer might result in 
other primary cancers discovered years after the treat-
ment of the first.13 In their report addressing a patient 
with 17 primary tumors, Nutting and colleagues14 
narrated a steeply increasing incidence of new tumor 
formation following delivery of tumoricidal therapy. 
In like manner, the contribution of radiation treat-
ment against one cancer on the subsequent occurrence 
of a second or third primary inside the radiation field 
cannot be dismissed.15 Radiation-related secondary 
tumors are typically seen after exposure to high doses 
of radiation in excess of 10 grays.16 Chemotherapeutic 
agents administered for the treatment of brain tumors 
have been linked to the subsequent development of 
leukemia.16 Furthermore, alkylating agents have been 
related to the development of subsequent malignancies 
and the potentiation of the carcinogenic effects of ra-
diotherapy on tissues.16 
The colon is the most common site for multiple pri-
mary malignant tumors.17 In addition, a high incidence 
of multiple primary tumors has been observed in pa-
tients with kidney cancer.13 Both tumors were found 
in our case report. Most of the primary malignancies 
reported in our paper were adenocarcinomas. After an 
adequate period of follow-up, we report encouraging 
survival in our patient. Similarly, Hao18 reported long-
term survival in a patient with six primary malignant 
tumors. 
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